This initiative aims to improve the diagnosis and management of colorectal cancer by developing a panel of immunohistochemistry assays targeting mismatch repair proteins (MMR). The MMR IHC Panel assists in identifying patients with Lynch syndrome or sporadic microsatellite instability-high tumors, guiding appropriate treatment decisions.